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Glioblastoma is aggressive, highly infiltrating, and the most frequent malignant form of
brain cancer. With a median survival time of only 14.6months, when treated with the
standard of care, it is essential to find new therapeutic options. A specific CDK4/6
inhibitor, PD0332991, obtained accelerated approval from the Food and Drug Adminis-
tration for the treatment of patients with advanced estrogen receptor-positive and HER2-
negative breast cancer. Common alterations in the cyclin D1-cyclin-dependent kinase
4/6-retinoblastoma 1 pathway in glioblastoma make PD0332991 also an interesting drug
for the treatment of glioblastoma. Promising results in in vitro studies, where patient
derived glioblastoma cell lines showed sensitivity to PD0332991, gave motive to start
in vivo studies. Outcomes of these studies have been contrasting in terms of PD0332991
efficacy within the brain: more research is necessary to conclude whether CDK4/6
inhibitor can be beneficial in the treatment of glioblastoma.
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INTRODUCTION
Glioblastoma (GBM, Astrocytoma grade IV) is an aggressive, highly infiltrating form of brain cancer.
Glioblastoma accounts for 15.6% of all primary brain tumors and, representing 45.2%, it is the most
frequent malignant brain tumor (1, 2). However, glioblastoma is an uncommon disease. With an
incidence rate of 3.19 per 100,000 in the US, it occurs over 21 times less often than breast cancer
(2, 3).
Today, the standard of care for glioblastoma consists of surgical resection followed by radiotherapy
in combination with temozolomide (4). Significant improvements to the standard treatment leading
to overall survival extension have been lacking. This devastating disease has a median survival time
of only 14.6months (4). It is, therefore, essential to find new therapeutic options. This review focuses
on the data on PD0332991 (Palbociclib) studies in glioblastoma and how this drug can play a role in
glioblastoma treatment.
THE CELL CYCLE
The normal cell cycle consists out of four phases, known as G1, S, G2, and M. Checkpoints regulate
progression to the next phase or initiate apoptosis (5). The cyclin D1-cyclin-dependent kinase 4/6-
retinoblastoma 1 (cycD1-CDK4/6-Rb1) signaling pathway covers an important checkpoint in the cell
cycle (6). It regulates G1 progression to S phase by a cascade of (in)activations (7) (Figure 1).
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FIGURE 1 | The cyclin D1-cyclin-dependent kinase 4/6-retinoblastoma
1 pathway. Abbreviations: M – mitosis; G1 – gap 1; S – synthesis; G2 – gap
2; Rb1 – retinoblastoma 1; CDK4/6 – cyclin-dependent kinase 4/6;
cycD1 – cyclin D1; P – phosphate group.
The main players in the cycD1-CDK4/6-Rb1 pathway are
CDK4/6, p16, p18, cycD1, Rb1, and E2F. Free CDK4/6 can be
inactivated by p16/18, or bind to cycD1 (8–11). The CDK4/6-
cycD1 complex phosphorylates the negative growth regulator Rb1
to inhibit it from binding transcription factor E2F (12). Free E2F
can then ultimately cause cell division (13).
The importance of CDK4/6 in cell cycle control makes it an
interesting target for cancer treatment (14). Alterations in cell’s
DNA can lead to cancer. These alterations cause cell division to
be dysregulated, whereby the cell’s mechanisms are not able to
control cell growth. Hyperactivity and amplification of CDK4/6,
even as their genomic instability, are mechanisms in which the
origin of cell cycle dysregulation can be found (15).
PD0332991
PD0332991 is a highly specific CDK4/6 inhibitor (16) devel-
oped by Pfizer for cancer treatment (17). The drug inhibits
CDK4/6, leading to inhibition of Rb1 phosphorylation and
eventually to cell cycle blockage (18). PD0332991 has been a
target of cancer research studies, especially within the field
of breast cancer (19, 20). In 2004, Pfizer launched the first
phase I clinical trial (ClinicalTrials.gov ID: NCT00141297).
This trial was, in 2008, followed by a phase I/II clinical trial,
named PALOMA-1, focusing on breast cancer treatment (21,
22). This clinical trial showed that PD0332991, as an addi-
tion to the breast cancer drug letrozole, significantly improved
progression free survival for patients with advanced estrogen
receptor-positive and HER2-negative breast cancer (22). Based
on the results of this trial, PD0332991 obtained accelerated
approval from the Food and Drug Administration (FDA) in
the USA in 2015. The approval was specific to this subgroup
of patients with breast cancer (23). Meanwhile, phase III trials
for PD0332991 usage in breast cancer and phase I and II trials
for PD0332991 treatment in other types of cancer have started
(Table 1).
TABLE 1 | Clinical trials for PD0332991.
Phase Type of cancer Name ClinicalTrials.gov ID
Phase I Colorectal – NCT01522989
Central nervous system – NCT02255461
Phase I/II Lung – NCT02022982
Head and neck – NCT02101034
Phase II Ovarian – NCT01536743
Prostate – NCT02059213
Glioblastoma – NCT01227434





Rb1 PREDICTS RESPONSE TO PD0332991
Preclinical studies on PD0332991 in breast cancer have shown
that Rb1 functioning is the determining factor for the efficacy of
treatment (24–27). Rb1 deficiency or loss of its function results
in PD0332991 resistance (24–27). Dean and colleagues, in 2010,
compared Rb1-deficient to Rb1-proficient cell lines for differ-
ences in PD0332991 treatment response, whereby, in most cell
lines, knockdown of Rb1 resulted in failure to stop proliferation
through CDK4/6 inhibition (24). Consistent with these results,
Roberts and colleagues observed in vivo that PD0332991 did not
reduce tumor growth in mice harboring Rb1-deficient tumors
(26). Witkiewicz and colleagues reconfirmed these outcomes with
the in vitro testing of PD0332991 on Rb1 knockdown and con-
trol cells (27). In line with these results, it has been shown that
changes in the cycD1-CDK4/6-Rb1 pathway, leading to elevated
expression of Rb1, are most sensitive to PD0332991 treatment
(28). These changes include higher levels of cycD1 and Rb1 and
lower levels of p16 (28). Presumably, p16 and Rb1 can be used as
markers to predict response to PD0332991 (25).
The Cancer GenomeAtlas ResearchNetwork (TCGA) revealed
in 2008 that the cycD1-CDK4/6-Rb1 pathway is, with alterations
in 78.9% of glioblastoma, among the top three most altered path-
ways (29, 30). The p15/16 location, within this pathway, is the
most common location for alteration (61%) (30). Other alter-
ations found within the cycD1-CDK4/6-Rb1 pathway areCDK4/6
(15.5%), Rb1 (7.6%), p18 (5.6%), and cyclins (2%) (30). Most of
these alterations promote the pathway, whichmakes this a suitable
aim for therapy.
In 2010, Michaud and colleagues published the first article on
PD0332991 use in glioblastoma (31). Through in vitro experi-
ments, they revealed the same strengths and weaknesses of this
drug as was found in breast cancer: PD0332991 inhibited cell pro-
liferation in Rb1 proficient glioblastoma cells and Rb1 deficiency
caused resistance (31). In addition, codeletion of p16 and p18 was,
by Wiedemeyer and colleagues, found to be another predictor of
increased sensitivity (32). A remarkable outcome of this study
was that high levels of CDK4 or CDK6 had no influence on the
sensitivity to PD0332991 (32). This data was supported with a
later study by Cen and colleagues who further suggested that
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CDK4 amplification can be a sign of high resistance, while CDK6
amplification can be a sign of high sensitivity (33). Based on the
genetic profiles of patient material, Verhaak and colleagues were
able to define a classification, creating subtypes for glioblastoma
(34). Codeletion of p16/18 was described to be highly associated
with one of the subtypes: classical glioblastoma (34). It will be
interesting to see in future experiments whether the classical
subtype of glioblastoma gain most benefit from treatment with
PD0332991.
In order to be an effective drug for glioblastoma, PD0332991
needs to have the ability to reach the tumor and thereby the
ability to cross the blood–brain barrier (BBB). Studies have shown
that PD0332991 is capable of crossing the BBB, but there are
conflicting ideas on the effectivity of PD0332991 within the brain
(31, 33, 35–37).
In 2010,Michaud and colleagues demonstrated that at a dose of
150mg/kg/day, PD0332991 acted as an effective antiproliferative
drug intracranially (31). The survival analysis, where survival time
of PD0332991 treated mice was significantly extended compared
to vehicle control mice, confirmed these findings (31). A study by
Cen and colleagues strongly supported these findings by recon-
firming the antiproliferative effect of PD0332991 in vivo and the
survival benefit of treatment (33).
Recently, various research groups have revisited PD0332991
and its effects within the brain. In vitro experiments showed that
PD0332991 is a substrate of P-glycoprotein (P-gp) and breast can-
cer resistance protein (BCRP), both efflux transporters in the BBB
(35–38). Through in vivo experiments, de Gooijer and colleagues
as well as Parrish and colleagues showed that P-gp and BCRP
cause limited PD0332991 delivery to the brain, resulting in low
drug concentrations (35, 36). Treated with 150mg/kg/day, the
restricted PD0332991 brain penetration was shown to be inade-
quate to reach antiproliferative effects or survival benefits (36). It
is not clear as to why the research groups have come to different
conclusions in regard to the ability of PD0332991 to cross the
blood–brain barrier. Patient-derived cell lines were intracranially
injected into immunocompromised all of the studies and the same
concentration of PD0332991 was used (150mg/kg/day). Further
studies are warranted.
To determine the efficacy of PD0332991, the University of
California in San Francisco had started a phase II clinical trial
in patients with Rb1 positive, recurrent glioblastoma (Table 1).
In December 2013, after 23 patients had been enrolled in this
trial, the investigators completed collecting their final data for
the primary outcome measure. We are still eagerly waiting for the
results of this clinical trial.
Overall, PD0332991 appears to be an interesting drug for
glioblastoma treatment and could be a valuable addition to the
standard of care. Raub and colleagues have tested PD0332991
in combination with temozolomide and unpublished data from
McDonald’s lab has shown significant efficacy using this CDK
4/6 inhibitor in combination with radiotherapy. In vivo stud-
ies with this combination have started. Although there is some
irregularity in the outcomes concerning PD0332991 crossing the
BBB, in vitro results are promising. New in vivo experiments,
advised in combination with P-gp and BCRP inhibitors, are rec-
ommended before more clinical trials on glioblastoma patients
start. The potential of PD0332991 in the treatment of glioblas-
toma is encouraging to continue investigating PD0332991 in
the hope of ultimately finding a cure for this devastating dis-
ease.
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